INMED PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
INMED PHARMACEUTICALS INC. (INM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $75.35 per share for the 12-month period ending 2025-06-30, per its S-4 filed 2026-07-02.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-07-02
- INMED PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2020 was 6.08 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|
| 2021-03-31 | 2.52 CAD/shares 10-Q · filed 2021-05-13 | ||
| 2020-12-31 | 2.52 CAD/shares 10-Q · filed 2021-02-11 | ||
| 2020-06-30 | 6.08 CAD/shares 10-K · filed 2021-09-24 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2025-06-30 | $75.35 S-4 · filed 2026-07-02 | |
| 2024-06-30 | $298.00 S-4 · filed 2026-07-02 | $14.90 10-K · filed 2024-09-30 |
| 2023-06-30 | $57.44 10-K · filed 2024-09-30 | |
| 2022-06-30 | $21.04 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $1.96 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |